anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
People with diabetes mellitus are more prone to coronary heart disease, stroke, and peripheral vascular disease, and diabetes mellitus has been regarded as an independent risk factor for the progression of coronary artery disease. Several studies have been reported that diabetes increased the risk of cardiovascular mortality in both men and women. With the introduction of drug-eluting stents (DESs), the angiographic rates of restenosis at later months have reduced dramatically in several studies. However, even with DESs, diabetic patients showed increased rates of restenosis and late loss index compared with nondiabetic patients. Diabetes has been considered to be a predictor of poor prognosis after percutaneous coronary intervention with drug-eluting stents. Long-term clinical and angiographic outcomes after percutaneous coronary intervention (PCI) with drug-metal stents (DESs) have been demonstrated to be worse in diabetic patients compared with nondiabetic patients. In the era of DESs, no study has demonstrated the clinical and angiographic outcomes in diabetic patients after DES implantation by using optical coherence tomography (OCT).

Various microRNAs such as miRNA-21, -126, -143, -145 are involved in the restenosis and atherosclerosis progression (Figure 1). Changes in these miRNAs from baseline to 9 months after randomization have never been studied, and the effects of pioglitazone in correlation with the changes in various miRNAs could be utilized in clinical practices. Comparison of pioglitazone and placebo on 9 months follow-up neointima volume and neointima characteristics by optical coherence tomography (OCT) will be conducted.
Participants receive placebo to pembrolizumab intravenously (IV) on Day 1 of each 3-week cycle (Q3W) for 6 cycles followed by placebo IV on Day 1 of each 6-week cycle (Q6W) for an additional 6 cycles. During the Q3W dosing period of placebo, participants receive concurrent standard of care (SoC) chemotherapy for 4 or 6 cycles. Participants optionally receive radiotherapy starting within 6 weeks of completion of SoC chemotherapy. The SoC chemotherapy regimen includes carboplatin AUC 5 or 6 IV Q3W plus paclitaxel 175 mg/m\^2 IV Q3W. In the event of severe hypersensitivity to, or an AE requiring discontinuation of, carboplatin or paclitaxel, cisplatin or docetaxel may be substituted after investigator consults with sponsor. The SoC radiotherapy regimen may include, at the discretion of the investigator, external beam radiotherapy (EBRT) ≥4500 cGY with variable dose frequency, with or without cisplatin 50 mg/m\^2 IV on days 1 and 29 of EBRT, and/or brachytherapy radiation.
Overactivation of the transforming growth factor-β (TGFβ) signaling in Duchenne muscular dystrophy (DMD) is a major hallmark of disease progression, leading to fibrosis and muscle dysfunction. Here, we investigated the role of SETDB1 (SET domain, bifurcated 1), a histone lysine methyltransferase involved in muscle differentiation. Our data show that, following TGFβ induction, SETDB1 accumulates in the nuclei of healthy myotubes while being already present in the nuclei of DMD myotubes where TGFβ signaling is constitutively activated. Transcriptomics revealed that depletion of SETDB1 in DMD myotubes leads to down-regulation of TGFβ target genes coding for secreted factors involved in extracellular matrix remodeling and inflammation. Consequently, SETDB1 silencing in DMD myotubes abrogates the deleterious effect of their secretome on myoblast differentiation by impairing myoblast pro-fibrotic response. Our findings indicate that SETDB1 potentiates the TGFβ-driven fibrotic response in DMD muscles, providing an additional axis for therapeutic intervention.
The invention relates to the technical field of medicines. Rheumatoid arthritis (RA) is one of key diseases which harm the human health at present, and search of high-efficiency low-toxicity medicines for preventing and treating the RA is an arduous task and problem in global medicine world. The invention discloses a preparation method and application of ethnopharmacological rhamnella gilgitica stem extract. The extract is prepared by the following steps: by using rhamnella gilgitica as a raw material, obtaining an extracting solution through a water extraction method, concentrating the extracting solution, loading a macroporous resin, eluting through 20-85 percent of ethanol, collecting the eluant, performing vacuum concentration, and performing vacuum drying to obtain the rhamnella gilgitica extract. The pharmacological experiment research proves that the rhamnella gilgitica extract in the invention has an effect of treating the RA. The invention provides a novel source for searching a novel medicine for treating the RA.
We have developed a model system of HIV reservoirs in neural cells by generating chimeric phosphorothioate-modified oligodeoxynucleotides (sODN) that specifically interact with neural cell DNA or RNA, and that further comprise a sequence of the HIV genome. In particular, we have conjugated the chimera sODN to a delivery vehicle (e.g. a superparamagnetic iron oxide nanoparticle (SPIO)) and have demonstrated specific delivery to neural cells, in vitro and in vivo. These model systems can be used to screen for agents that specifically target latent viral infection. In particular, using the model system, we have developed suicide MRI contrast agents that can be used to reduce the number of neural cells which harbor the virus, also provided herein. Our model system is translatable to other latent viruses as well.
PURPOSE: A stabilizing composition of tetrahydrobiopterin and analysis method of tetrahydrobiopterin using the same are provided to be used for physiology pathological function research of the tetrahydrobiopterin. CONSTITUTION: A stabilizing composition of tetrahydrobiopterin comprises acid compound having the pH of 1.5-6.5 and dithioerythritol. The acid compound is hydrochloric acid. The acid compound is weak acid compound having the pH of 3.0-5.5. The weak acid compound is &egr;-acetamidocarproic acid or ascorbic acid. The diothioerythritol and acid compound are included in acetonitrile. The composition includes the acetonitrile having the volume of 1-20 times of the tetrahydrobiopterin. The analysis method of tetrahydrobiopterin comprises the following steps: stabilizing the tetrahydrobiopterin by processing the stabilizing composition on a sample including the tetrahydrobiopterin collected from an analyte; injecting the sample into a column of the liquid chromatography; separating tetrahydrobiopterin by spilling the moving phase of the liquid chromatography; and analyzing the separated tetrahydrobiopterin by using a mass spectrograph. The analysis method maintains the temperature as 2-20 deg. Celsius.
An out-of-bed identification system and an out-of-bed identification method are provided. The out-of-bed identification system includes an image capturing unit and an identification unit that is electrically coupled to the image capturing unit. The image capturing unit can obtain a real-time image information that is two-dimensional. The real-time image information includes an image data of a hospital bed and an image data of a patient. The identification unit includes a detection module and a judgment module that is electrically coupled to the detection module. The detection module can create a hospital bed area by using the image data of the hospital bed, and can create a left wide joint point and a right wide joint point by using the image data of the patient. The judgment module can judge the location of the left wide joint point and the right wide joint point. When the judgment module judges that the left wide joint point and the right wide joint point are not located in the hospital bed area, the judgment module can send out a bed out signal. Accordingly, the out-of-bed identification system can effectively identify and monitor whether patient gets out of bed without permission.
Major innovations in radiotherapy (RT) delivery (3D conformal RT, intensity modulated RT) now permit RT dose escalation to be tested as a means of improving disease control in many tumour sites. With delivery innovations, life-threatening toxicity occurs rarely, but significant clinical toxicity is common. In previous work the investigators have studied a cohort of 98 prostate patients who received dose-escalated 3D-CRT and have obtained evidence of genetic and dosimetric factors underlying rectal/bladder toxicity. They posit that the late radiation toxicity disease state has significant genetic determinants in other malignancies. These determinants are neither understood nor accounted for in selection of treatment, and the investigators propose to study additional well-characterized cohorts, who are clinically well from a disease control perspective, given that comprehensive dosimetric and outcome information is available on all.

For a thorough understanding of the molecular processes underlying tissue responses to radiation damage, the investigators propose a genomic analysis. Their working hypothesis is that normal organ toxicity will be associated with patient genetics as measured by single nucleotide polymorphisms (SNPs) in a select group of genes. The criteria for selecting SNPs will be based on a candidate gene approach, choosing genes implicated or demonstrated in DNA repair pathways and radiation-induced tissue damage/tissue homeostasis. Analysis of these data will use both statistically based bioinformatics approaches.
The invention discloses a traditional Chinese medicine composition for preventing and treating vascular dementia. The traditional Chinese medicine composition for preventing and treating vascular dementia comprises ginseng, gastrodia elata, Euonymus alatus and Ligusticum wallichii. The composition can be prepared into Chinese herbal preparation crude drug for preventing and treating vascular dementia. The ginseng and the Ligusticum wallichii are extracted with alcohol, the gastrodia elata and the Euonymus alatus are extracted with water, the obtained alcohol extract and the obtained water extract are mixed, the mixture is dried under vacuum and then is pulverized to obtain the final product, and the composition can be directly taken orally or is prepared into other dosage forms such as granules, capsules, soft capsules, electuaries, pills and decocted extracts. The composition is completely prepared from natural medicinal plants, does not contain hormones, and does not contain other chemical synthetic products such as pigment, and even if a patient orally takes the composition continuously, no toxic and side effect is performed on the human body. The traditional Chinese medicine composition contains various easily absorbable ingredients such as ginsenoside, chuanxiongol, chuanxiongzine, gastrodin and quercetin, can be effectively used for treating the vascular dementia, increases cerebral blood flow, reduces cerebral vascular resistance, improves body immunocompetence, and has effects of tonifying deficiency, promoting intelligence, suppressing the hyperactive liver, subsiding Yang, dispelling blood stasis and dredging collaterals.
Patients undergo leukapheresis to obtain autologous lymphokine-activated killer (LAK) cells, followed 3-7 days later by therapeutic craniotomy. The autologous LAK cells are then instilled into the tumor bed cavity at the time of therapeutic craniotomy.
Residual significant mitral regurgitation (MR) can increase the risk of adverse events after transcatheter aortic valve replacement (TAVR). The clinical benefits of staged transcatheter edge-to-edge repair (TEER) after TAVR remain underexplored. This study aimed to investigate the clinical outcomes of staged TEER for residual significant MR after TAVR. This observational study included 314 consecutive patients with chronic residual grade 3+ or 4+ MR at the 30-day follow-up after TAVR, with 104 patients (33.1%) treated with staged TEER (TEER group) and 210 (66.9%) with medical therapy alone. The primary composite outcomes were all-cause mortality and heart failure hospitalization at 2 years. Additional analysis, including changes in MR grade and the New York Association functional classification, and subgroup outcome comparisons based on MR etiology were also conducted. In our study, the rate of primary composite outcome was lower in the TEER group than in the medical therapy alone group (33.7% vs 48.1%, p = 0.015). Significant improvement in MR grade and New York Association class was observed in the TEER group after 2 years. The subgroup analysis demonstrated that in patients with degenerative MR, a lower incidence of composite outcome and heart failure hospitalization was observed in the TEER group (hazard ratio 0.35, 95% confidence interval 0.23 to 0.53, p <0.001). In conclusion, staged TEER after TAVR was associated with reduced MR and improved clinical outcomes. The clinical significance of MR after TAVR should be carefully evaluated, and TEER should be considered for patients with significant residual MR, particularly, those with degenerative MR.
A total of 108 children aged from 7 to 16 years old were included in this study and equally divided into two groups: Group I (asthmatic children) and Group II (healthy control). All the children were clinically examined to assess their dental caries experience and periodontal health condition. A trained and calibrated examiner (kappa = 0.95) performed the dental caries examination according to World Health Organization (WHO) criteria. Dental caries status was recorded using the number of decayed, missing or filled teeth (dmft/DMFT) and decayed, missing or filled surface (dmfs/DMFS) indices. Periodontal health was assessed by gingival index \[GI\] and plaque index(PI). An interview was conducted with parents/guardians and a structured questionnaire was employed to parents in addition to medical records. Stimulated salivary samples were collected and assessed for salivary flow rate, salivary pH and buffering capacity.
Pazopanib is an oral inhibitor of multiple receptor tyrosine kinases, including vascular endothelial growth factor receptor VEGFR-1, VEGFR-2, and VEGFR-3 at therapeutic plasma concentrations. These receptors are implicated in pathologic angiogenesis, tumor growth, and cancer progression. Pazopanib is approved for the treatment of advanced soft tissue sarcoma, following progression on one prior systemic therapy, based on improved progression free survival. TRC105 is an antibody to CD105, an important angiogenic target on vascular endothelial cells that is distinct from VEGFR. TRC105 inhibits angiogenesis, tumor growth and metastases in preclinical models and complements the activity of bevacizumab and multi-kinase inhibitors that target the VEGFR. In a phase 1 study of advanced solid tumors, TRC105 therapy caused a global reduction in angiogenic biomarkers and reduced tumor burden at doses that were well-tolerated. In a phase 1b study, the combination of TRC105 and bevacizumab produced radiographic reductions in tumor volume in bevacizumab-refractory patients, and was well tolerated. TRC105 potentiates bevacizumab and VEGFR tyrosine kinases (VEGFR TKI) in preclinical models. By targeting a non-VEGF pathway that is upregulated following VEGF inhibition, TRC105 has the potential to complement VEGFR TKIs and could represent a major advance in cancer therapy. Together, the use of TRC105 with pazopanib may result in more effective angiogenesis inhibition and improved clinical efficacy over that seen with pazopanib alone.
The compound is used in the pharmaceutical industry. By the method equivalent quantities 2-diethylaminoethyl chloride hydrochloride and thiocarbamide are heated together in an aqueous medium for 4 h at from 80 to 85 degrees C. The reaction mass produced is cooled, the crystals are separated by filtration and are dried. The filtrate produced is added to the subsequent synthesis in the stage of the reaction mass cooling. The total yield of 2-diethylaminoethylisothiouranium chloride hydrochloride is over 98%. The melting temperature is 190-194 degrees C. The purity of the product exceeds 96%. 1 claim
There is increasing recognition of the high burden of psychological distress among populations around the world. Increasingly, non-specialists (persons who do not have expertise in formal mental health training) are being used to deliver psychological services. There is a long history of successful implementation of psychological services by non-specialists in Nepal. Recently, a cluster randomized controlled trial of Problem Management Plus showed modest benefit over enhanced care as usual in southeastern Nepal. A recent initiative by the World Health Organization is being rolled out to improve the competencies of non-specialists participating in Problem Management Plus and similar trainings. This initiative is Ensuring Quality in Psychological Services (Equip). The proposed study in Nepal will evaluate if non-specialists participating in Equip-based Problem Management Plus training show greater competencies compared to non-specialists participating in standard Problem Management Plus training. The proposed study is a randomized controlled trial with mixed-methods components evaluating both quantitative outcomes and qualitative outcomes among non-specialists participating in the training and their trainers.
Participants in the standard of care arm will receive a referral letter to their local Department of Health (DoH) clinic to continue TPT. They will be instructed to present to the DoH clinic within 2 weeks to receive their continuation doses of TPT per current South African DoH standard of care (refills administered monthly).
A method and system for providing community support for the primary user of a respiratory device is disclosed. Operational data from use of a respiratory therapy device by a primary user in accordance with complying with a respiratory treatment plan is collected. A secondary user, such as a friend or family member is linked to the primary user. Effectiveness data is determined from the collected operational data. The effectiveness data shows the effectiveness of the respiratory therapy device in relation to the respiratory treatment plan. The effectiveness data is sent to a user device operated by the secondary user. An interface is generated to allow the secondary user to view the effectiveness data.
As with any NSAID, caution should be exercised in treating the elderly (65 years and older). Most spontaneous reports of fatal GI events with NSAIDs are in the elderly or debilitated patients and, therefore, care should be taken in treating this population. In addition to a past history of ulcer disease, older age and poor general health status (among other factors) may increase the risk for GI bleeding. To minimize the potential risk of an adverse GI event, the lowest effective dose should be used for the shortest possible duration (see WARNINGS, Gastrointestinal Effects – Risk of GI Ulceration,Bleeding and Perforation).

As with all other NSAIDs, there is a risk of developing renal toxicity in patients in which renal prostaglandins have a compensatory role in maintenance of renal perfusion. Discontinuation of non-steroidal anti-inflammatory drug therapy is usually followed by recovery to the pretreatment state (see WARNINGS, Renal Effects).

In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting a greater frequency of impaired drug elimination and of concomitant disease or other drug therapy.
Participants will engage in 3 sessions per week (2 EX, 1 DIET, totaling 4 hours per week), consisting of two virtual group sessions (totaling 3 hours) and one independent session (1 hour) (Table 1). Virtual group sessions will occur in groups of 6-8 participants using the Zoom Healthcare platform (on a computer or tablet).
The present invention relates to a novel class of hydroxamic acid derivatives.  The hydroxamic acid compounds can be used to treat cancer. The hydroxamic acid compounds can also inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention are also useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the hydroxamic acid derivatives and safe dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of the hydroxamic acid derivatives in vivo.
Patients with MF/SS who were previously treated with brentuximab vedotin. Up to 10 patients will be enrolled onto this cohort. Following identification of a promising dose after the completion of the full Cohort 1 Simon two stage design, enrollment will initiate onto cohort 2 at the dose found to be promising in cohort 1. For MF patients: Treatment delays lasting longer than 8 weeks for toxicity will result in removal from study. The 0.9mg/kg dose did not meet the primary endpoint for response, therefore 1.2 mg/kg has been chosen as the dose for Cohort 2. As of October 2020, enrollment on our exploratory Cohort 2 has opened at the 1.2 mg/kg dose.
Patients receive RP-6306 with Debio 0123 orally until disease progression, unacceptable toxicity, or investigator/patient decision. Dose escalation will proceed until a maximum tolerated dose is identified.
PURPOSE: We aim to establish diagnostic thresholds of sarcopenia and myosteatosis based on CT measurements, and to validate their prognostic value in a large cohort of kidney transplant recipients.
METHODS: Local healthy population with abdominal CT between 2010 and 2022, and patients underwent kidney transplantation between 2015 and 2019 at our center were retrospectively included. The skeletal muscle index and muscle attenuation of abdominal muscles were calculated based on CT image at the middle of the third lumbar vertebra. Primary endpoints included all-cause mortality and death censored allograft survival.
RESULTS: Age- and sex-specific thresholds for sarcopenia and myosteatosis were established based on 1598 healthy local population. The final patient cohort consisted of 992 kidney transplant recipients (median age 34 years, interquartile range 28-44 years; 694 males), including 33 (3.3%) with sarcopenia and 95 (9.5%) with myosteatosis. Multivariate analysis revealed myosteatosis (adjusted hazard ratio = 3.08, p = 0.022) was an independent baseline risk factor of mortality after adjusting for age, the history of cancer, and the history of cardiovascular event. Multivariate analysis found preemptive transplantation (adjusted hazard ratio = 0.36, p = 0.037) was an independent protective factor of allograft loss. No difference was found in the prognosis between kidney transplant recipients with and without sarcopenia.
CONCLUSION: Myosteatosis was an independent risk factor of mortality after kidney transplantation, but sarcopenia was not. Neither sarcopenia nor myosteatosis was associated with graft loss.